Negative symptoms in schizophrenia : considerations for clinical trials : working group on negative symptoms in schizophrenia

There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treat...

Full description

Saved in:

Bibliographic Details
Published in:	Psychopharmacologia Vol. 115; no. 1-2; pp. 221 - 228
Main Authors:	MÖLLER, H.-J, VAN PRAAG, H. M, GERLACH, J, GRAFFORD, K, HENTSCHEL, B, HERTKORN, A, HEYLEN, S, LECRUBIER, Y, LEONARD, J. P, MCKENNA, P, MAIER, W, PEDERSEN, V, AUFDEMBRINKE, B, RAPPARD, A, REIN, W, RYAN, J, NIELSEN, M. S, STIEGLITZ, R.-D, WEGENER, G, WILSON, J, BAILEY, P, BARNES, T. R. E, BECK, J, BENTSEN, H, EICH, F. X, FARROW, L, FLEISCHHACKER, W. W
Format:	Journal Article
Language:	English
Published:	Berlin Springer 01-06-1994
Subjects:	Biological and medical sciences Clinical Trials as Topic Humans Medical sciences Neuropharmacology Pharmacology. Drug treatments Psychiatric Status Rating Scales Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopharmacology Research Design Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Human Methodology Evaluation scale Neuroleptic Psychotropic Treatment efficiency Schizophrenia Psychosis Chemotherapy Negative symptom Clinical trial Diagnosis Therapeutic protocol
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	0033-3158 1432-2072
DOI:	10.1007/BF02244775